Venous needle dislodgement (VND) occurs when a venous needle dislodges from a patient's vascular access during hemodialysis treatment. This report discusses VND severity and presents best practices and other solutions to mitigate this important issue, which is responsible for serious injury and mortality among dialysis patients.
Presents and discusses severity of VND
Discusses ramifications to patients, health care workers, and facilities
Presents best practices and solutions to mitigate VND
About the Author
Michael Morales, CHT, CCHT-A, CCNT, CBNT, is CEO of Dialysis Education Services, an interdisciplinary dialysis education facility in Bellflower, Calif. Grace Padilla-Kastenberg, MPH, is president of Marea Enterprises Inc., a public health medical device company focused on healthcare and patient safety issues headquartered in Thousand Oaks, Calif.
About the Underwriter
Redsense Medical Inc. is the innovator in the development and manufacturing of blood-loss-detection devices. Redsense is the only clinically trialed blood detection alarm used for monitoring the patient's access during hemodialysis. Its products are used in clinics and homes throughout the United States, Canada, Europe Asia, and Asia Pacific. Redsense Medical was founded in 2006 and is based in Chicago and Halmstad, Sweden.